Kenvue (KVUE) Q2 2026 earnings review
Volume Returns, But Margin Compression and Merger Cloud the Picture
Kenvue delivered its third consecutive quarter of organic sales growth (+1.6%), but the real headline is the inflection in volume. Total volume grew 0.7%, finally reversing the steep declines seen throughout 2025. The Skin Health & Beauty segment led the turnaround with 3.7% organic growth. However, the top-line recovery didn't translate to operational leverage. Adjusted gross margin contracted by 70 basis points to 60.2%, dragged down by inflation and tariffs. EPS growth to $0.31 relied heavily on a lower effective tax rate rather than operational efficiency. With the Kimberly-Clark acquisition pending for Q4 2026, management has suspended all forward guidance, leaving investors flying blind on the near-term margin trajectory.
🐂 Bull Case
Total volume grew 0.7%, a critical inflection point after quarters of sharp declines (e.g., -3.3% in 25Q2). The fundamental 'back-to-basics' CPG turnaround is taking hold.
Previously a major laggard, Skin Health & Beauty grew organic sales 3.7% driven by 1.0% volume growth. Neutrogena household penetration improved for the third consecutive quarter.
🐻 Bear Case
Adjusted gross margin fell from 60.9% to 60.2%, and adjusted operating margin fell from 22.7% to 22.1%. Inflation and tariffs are eroding the benefits of volume leverage.
The pending Kimberly-Clark merger has forced Kenvue to suspend guidance and cancel its earnings call, leaving investors without visibility into current operational execution or tariff impacts.
⚖️ Verdict: ⚪
Stable. The volume turnaround proves management's strategy is working at the shelf, but persistent margin pressure and the pending Kimberly-Clark acquisition make Kenvue a merger arbitrage play rather than a pure fundamental investment.
Key Themes
Skin Health & Beauty Leads the Recovery
Skin Health & Beauty was the standout segment, accelerating from a -3.7% organic decline a year ago to +3.7% growth this quarter. This was fueled by 2.7% positive pricing and a 1.0% volume increase. Strong eCommerce execution and innovations like OGX Pro Growth + Peptide and Neutrogena Ultra Sheer Sun are driving this turnaround, marking a successful shift in brand-building strategy.
FDA Approval of Tylenol with Naproxen
A major product innovation milestone: Kenvue secured FDA approval for Tylenol with Naproxen, the first OTC fixed-dose combination of acetaminophen and naproxen sodium. Backed by a three-year exclusivity period, this premium, science-backed product should serve as a significant mix-driver for the Self Care segment over the next 12-24 months.
eCommerce and Market Share Momentum
Better go-to-market execution is yielding results in core brands. Zyrtec continues to gain share in the Allergy category despite a dynamic macro environment. Tylenol consumption trends improved sequentially, resulting in slight market share gains vs the prior year. Management specifically highlighted strong momentum in the eCommerce channel across multiple segments.
Margin Contraction Contradicts Volume Recovery
Despite returning to volume growth (+0.7%) and maintaining positive pricing (+0.9%), Adjusted Gross Profit Margin contracted by 70 basis points year-over-year to 60.2%. This breaks the narrative that top-line recovery would naturally restore margins. The drop flowed through to Adjusted Operating Margin, which fell from 22.7% to 22.1%, showing that cost optimization actions couldn't offset input cost pressures.
Self Care Volumes Still Shrinking
While overall company volume turned positive, the Self Care segment—Kenvue's largest profit engine—remains a laggard. Organic sales grew a tepid 0.6%, driven entirely by pricing (+1.2%), while volume actually declined 0.6%. The segment continues to struggle with historically low out-of-season incidences in Pain and Cough/Cold.
Macro Pressures: Tariffs and Transactional FX
Management explicitly blamed the gross margin contraction on inflation, tariffs, and unfavorable transactional foreign exchange. While translational FX provided a 1.4% top-line benefit, the underlying cost of moving goods across borders is rising, highlighting vulnerability to ongoing global trade tensions.
Information Vacuum Ahead of Merger
With the Kimberly-Clark merger pending, management has gone dark. The company canceled its earnings call and suspended all forward-looking guidance. Investors have no visibility into how the $250M '2026 Restructuring Initiative' is progressing or if current margin pressures will accelerate in the back half of the year.
Other KPIs
Accelerating. Free cash flow improved significantly from $0.8B in the prior year period. Operating cash flow rose to $1.2B (from $1.0B) driven by higher net income, effectively offsetting a higher use of working capital. Capital expenditures were tightly managed at $0.2B.
Decelerating. A significant drop from 26.9% in the prior year period. This favorable jurisdictional mix and valuation allowance release was the primary reason Adjusted Diluted EPS grew 7% to $0.31, masking the underlying deterioration in operating margins.
Guidance
Management has formally withdrawn all forward-looking financial targets due to the pending acquisition by Kimberly-Clark. No top-line, margin, or EPS forecasts were provided for Q3 or the full year.
The transaction is expected to close in the fourth quarter of 2026. Shareholders have approved the deal, and the HSR waiting period expired in February 2026, leaving only foreign regulatory approvals and customary closing conditions.
Key Questions
Tariff Margin Squeeze
Gross margins contracted by 70 bps partly due to tariffs. What is the annualized dollar impact of current tariffs, and do you have the pricing power to offset them before the merger closes?
Self Care Volume Weakness
Self Care was the only segment to experience volume declines (-0.6%) this quarter. Is this purely a function of weak seasonal incidences, or are you seeing trade-down behavior to private label?
Tylenol with Naproxen Rollout
With the FDA approval of Tylenol with Naproxen, how much cannibalization of the existing Tylenol base business are you forecasting versus incremental new category growth?
Restructuring Status
You recorded $69 million in restructuring expenses this quarter against the $250 million planned for the 2026 Restructuring Initiative. Are the operational efficiencies from this program tracking in line with initial expectations to offset supply chain inflation?